Hycor casts off urinalysis to focus on allergy and autoimmune testing
This article was originally published in Clinica
In vitro diagnostics firm Hycor has divested its urinalysis business in a bid to focus on the faster-growing allergy and autoimmune sectors. The unit, sold to a private equity consortium comprising One Rock Capital Partners, Laurel Crown Partners and StoneCreek Capital, includes Hycor's KOVA urinalysis products; the new business will be named Kova International and will be led by former Hycor executive Vance Mitchell. Financial terms were not disclosed.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.